- <![CDATA[FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer]]><![CDATA[The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.]]>onclive · 2mo ago↗ source
- <![CDATA[Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CIS]]><![CDATA[TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff. ]]>onclive · 2mo ago↗ source
- <![CDATA[Roswell Park Team Members Take Part in Global Conference Dedicated to Indigenous Peoples and Cancer]]><![CDATA[Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.]]>